WebCinqair: Reslizumab belongs to the class of medications called monoclonal antibodies. Specifically, it is an interleukin-5 inhibitor. It is used in addition to other medications to treat the symptoms of a type of asthma called eosinophilic asthma. This medication may be used when other "preventer" asthma medications, such as long-acting bronchodilators and … WebCinqair is also a medication for patients with eosinophilic asthma. It also works by reducing the number of eosinophils in your blood. Cinqair is administered as an intravenous (IV, or through the vein) infusion. It takes about 20 to 50 minutes to receive the infusion. It is given once every 4 weeks.
Chronic Asthma Treatment: Common Questions and Answers AAFP
WebThe study uses data from the FDA. It is based on ergoloid mesylates and reslizumab (the active ingredients of Gerimal and Cinqair, respectively), and Gerimal and Cinqair (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. WebFind 4 user ratings and reviews for Cinqair Intravenous on WebMD including side effects and drug interactions, medication effectiveness, ease of use and satisfaction pork loin chops with cream of mushroom soup
Reference ID: 3906489 - Food and Drug Administration
WebCinqair Prior Authorization Request CVS Caremark administers the prescription benefit plan for the patient identified. This patient’s benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the Web4. Cinqair (reslizumab): 10 mg/mL vial - concentrate for solution for intravenous infusion [product monograph]. Montreal: Teva Canada Limited; 2016 Jul 20. 5. Clinical Study Report: 3081. A 16-week, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as ... WebCINQAIR Product Monograph Page 5 of 30 CINQAIR™ should be discontinued in patients who experience a serious hypersensitivity reaction to reslizumab or to any of the excipients (see CONTRAINDICATIONS). The Teva Support Solutions™ program has been established to facilitate the administration of CINQAIR™ pork loin cooking time and temp